<div id="readability-page-1">Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.<h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> The Phase 2 study “A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F” tests if ifinatamab deruxtecan can help people with advanced esophageal squamous cell cancer. It focuses on tumor response in patients who have already tried other treatments, a high-need group with few options. The trial evaluates ifinatamab deruxtecan, also called I-DXd, an antibody-drug conjugate given by IV infusion every three weeks. It also allows standard rescue drugs to manage nausea and other side effects so participants can stay on treatment longer and show a clearer benefit-risk profile. The design is interventional with a single treatment arm and no randomization, so everyone receives I-DXd rather than standard care or placebo. The study is open label with no masking, and the main goal is to see if the drug shrinks or clears tumors in this late-line esophageal cancer setting. The study was first submitted on 5 February 2026 as the recruiting phase began, marking the start of patient enrollment. The latest update was filed on 15 April 2026, signaling protocol updates and confirming the trial remains active and relevant for tracking pipeline progress. For investors, this update adds another late-stage asset to Daiichi Sankyo’s growing antibody-drug conjugate franchise, which already drives much of its valuation. Positive data here could support new indications, strengthen bargaining power with partners like Merck, and intensify competition with ADC players in gastrointestinal cancers such as AstraZeneca and Seagen. In the near term, the stock impact may be modest as the study is still early, but regular updates can support sentiment around pipeline depth and deal potential. Investors should watch for interim response data and safety trends, as strong signals could lift expectations for long-term revenue and strategic partnerships in the ADC space. This study is currently recruiting and remains active, with full details and ongoing updates available on the ClinicalTrials.gov portal. To learn more about DSKYF’s potential, visit the Daiichi Sankyo Company drug pipeline page.</div>

4568

DSNKY

Daiichi Sankyo announced a Phase 2 clinical study for ifinatamab deruxtecan (I-DXd) targeting advanced esophageal squamous cell cancer. The open-label trial evaluates tumor response in patients who have undergone prior treatments. The study aims to assess the drug's efficacy and safety, with updates indicating active recruitment. This development enhances Daiichi Sankyo's ADC pipeline, potentially increasing its market value and competitive position against firms like Merck and AstraZeneca. Investors should monitor interim data for insights into long-term revenue prospects and partnerships.

Daiichi Sankyo Advances ADC Pipeline With New Esophageal Cancer Study